ACTG presents CroI in CroI in CroI in CroI in CroI to improve the aging results between people living in HIV and CMV (Cytomegalovirus)

Item content

Los Angeles, 12 March 2025 (Globe Newswire) – A global clinical trial network aimed at ACTG, HIV and other infectious diseases, can improve the immune system and physical health in people living with HIV today. The results of the study, the results of the A5383, appeared as a verbal abstract, “An ageration associated with aging related aging related to aging aging associated with the aging aging associated with the aging associated with the ages associated with the aging associated with the aging associated with the aging associated with an aging.

Item content

Item content

Item content

CMV is a common virus carried out by 95 percent of people living with most adults and HIV. Before the application of effective antiretrovirus therapy (art), CMV often caused vital dangerous conditions in the eyes, in the eyes, brain and intestines in those with developed HIV. The art strongly reduces these cases by strengthening the immune system, CMV can still affect the immune function, and noticeable symptoms can contribute inflammation. Letermovir is a drug approved by the Food and Drug Department (FDA) to prevent CMV infections and diseases in people.

“It improves immune recovery and functional status in people living with HIV, which is an important finding and an especially excited of an ACTG,” Said Keysepse Department, MD, North Carolina University. “It takes greater work to confirm these results; if they do, this intervention can make an important progress in HIV and aging research.”

Item content

Item content

A5383 is designed to restore the research, phase 2, randomized, open labeled, and immunized in people who do not have the inflammation of the letermovir and non-HIV HIV. Participants were randomly assigned to the reception of Letermovir every day for 48 weeks or any CMV treatment. Although the initial analysis first shows a temporary increase in inflammation marks, continuous treatment caused continuous reductions in improving inflammation and immunity and physical function.

Today’s presentation, CD4 in CD4, CD4 T-cells, CD4 T cells show that the number of CD4, which is most beneficial in persons and individuals. In addition, letermovir adopters showed improvements in CD4 / CD8 (expansence of People in HIV and elderly people, including cancer and deaths). Also, in which these useful effects are closely connected, improving immunological development, improving the physical function, these useful effects indicates closely closing.

Item content

“Despite modern treatment in people in the last 20 years, we are working to eliminate age and premature deaths in people living with HIV,” said Sarah Gianella, MD, California University of San Diego A5383, co-chairs of teaching A5383. “In particular, this is more of the immunological developments in women, because in the adoption of HIV, there are more inflammatory and more in the general population.

A5383 A5383, Dr. Gianella and Peter Hunt, University of MD, California headed by San Francisco (protocol chair). ACTG, Dr. Eron and Rajesh T. Gandhi, MD, Massachusetts General Hospital and Harvard Medical School (ACTG Vice Chair). This is the Institute of National Allergy and Infectious Diseases (NIH) National Allergy and Infectious Diseases (NIAID ACTG) UM1 AI068636, UM1 AI107716 and UM1 AI068634. Teaching drugs are equipped by Merck & Co., Inc., Rahway, NJ, USA.

Item content

About Untquake

ACTG is the largest and most long-term clinical network of clinical trials that are aimed at HIV and other infectious diseases and people living with them. Funded by Niaid and NIH institutions. Founded in 1987, the ACTG investigates HIV management and its commander’s leadership; To develop a treatment for HIV; Tuberculosis of tuberculosis, hepatitis B and the treatment of innovation for infectious diseases. This consists of a researcher and community members dedicated to Roman-treatments for infectious diseases in four continents and a community community for healthy diseases, which is the ultimate goal of the development of science that has a negative impact on the lives of our services.

Refusal: This content is only the responsibility of the actual and does not necessarily represent the official views of the NIH.

Media Contact:
Rachel Reiss, ACTG
Fleriss@mednet.ucla.edu

Item content